药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

交易中 09-22 14:01:24

10.790

-0.330

-2.97%

最高11.250	最低10.610	成交量839.90万
今开11.030	昨收11.120	日振幅5.76%
总市值43.92亿	流通市值33.66亿	总股本4.07亿
成交额9,078万	换手率2.69%	流通股本3.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":10.79,"timestamp":1790056871460,"preClose":11.12,"halted":0,"volume":8399000,"delay":0,"changeRate":-0.029676258992805765,"floatShares":312000000,"shares":407000000,"eps":-0.890295423524059,"marketStatus":"交易中","change":-0.33,"latestTime":"09-22 14:01:24","open":11.03,"high":11.25,"low":10.61,"amount":90783745,"amplitude":0.057554,"askPrice":10.8,"askSize":500,"bidPrice":10.78,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.787880992343777,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790064600000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":11.12,"openAndCloseTimeList":[[1790040600000,1790049600000],[1790053200000,1790064000000]],"volumeRatio":1.207455,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617/tweets","defaultTab":"tweets","newsList":[{"id":"1107407294","title":"药捷安康-B2026年中期营收0.35亿元，经调整净亏损0.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107407294","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107407294?lang=zh_cn&edition=full","pubTime":"2026-09-21 20:13","pubTimestamp":1789992799,"startTime":"0","endTime":"0","summary":"2026年上半年，药捷安康-B实现营收人民币3545.50万元，而上年同期尚无收入。本期经调整净亏损约人民币0.95亿元，较上年同期的经调整净亏损进一步收窄。经营活动现金流出净额约为人民币1.06亿元，较上年同期的1.09亿元小幅改善。成本结构方面，报告期内研发投入约人民币1.10亿元，同比上升11.7%，研发投入占收入比超过3100%。管理费用约人民币2306.00万元，同比下降约16.1%。主要收入来自与合作及授权协议相关的一次性预付款收入合计人民币3545.50万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B2026年中期营收0.35亿元，经调整净亏损0.95亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315301","title":"港股异动 | 药捷安康-B(02617)涨超11% 替恩戈替尼mCRPC中国II期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669315301?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:37","pubTimestamp":1789958272,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B(02617)涨超11%，截至发稿，涨11.37%，报11.17港元，成交额1.03亿港元。消息面上，9月18日晚，药捷安康公告，公司核心产品替恩戈替尼(捷恩泰®， Tinengotinib, TT-00420)联合新型内分泌治疗(NHT)用于经治后进展的转移性去势抵抗性前列腺癌(mCRPC)中国II期临床试验，于近日完成首例患者给药。此外，9月17日，药捷安康宣布，其核心产品捷恩泰®（替恩戈替尼片）首批产品正式从商业渠道发货，发往全国各地药房，捷恩泰®正式开启全国商业化供应，标志着这款全球首个解决FGFR抑制剂耐药的胆管癌靶向药即将陆续抵达全国各地患者手中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","KCAI","02617","VXUS","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923201","title":"药捷安康-B：捷恩泰获纳入CSCO胆道恶性肿瘤诊疗指南(2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923201","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668923201?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:05","pubTimestamp":1789733100,"startTime":"0","endTime":"0","summary":"9月18日，药捷安康-B（02617）发布公告，公司自主研发的捷恩泰?（替恩戈替尼）被纳入《中国临床肿瘤学会（CSCO）胆道恶性肿瘤诊疗指南（2026）》，作为晚期胆道恶性肿瘤治疗的II级推荐2A类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878777228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878777228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142095939","title":"药捷安康-B（02617）完成替恩戈替尼联合NHT治疗mCRPC中国Ⅱ期临床首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1142095939","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142095939?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:55","pubTimestamp":1789728930,"startTime":"0","endTime":"0","summary":"2026年9月18日，药捷安康-B公告称，公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国Ⅱ期临床试验已完成首例患者给药。替恩戈替尼是全球首个同时抑制FGFR/JAK通路并已在mCRPC中显示临床疗效的多靶点小分子激酶抑制剂。替恩戈替尼单药治疗mCRPC已于2025年6月获得美国FDA快速通道资格。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668894069","title":"药捷安康-B(02617)：替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2668894069","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668894069?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:54","pubTimestamp":1789728877,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，本公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国II期临床试验，于近日完成首例患者给药。其中新型内分泌治疗药物虽可显著延长患者生存期，为当前mCRPC一线核心治疗方案，但绝大多数患者最终会发生获得性耐药。替恩戈替尼单一疗法已在既往接受过多线治疗的mCRPC患者显出令人鼓舞的抗肿瘤疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBQ","IBBJ","02617","BMED","MDTX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668794056","title":"药捷安康-B(02617.HK)：捷恩泰®(替恩戈替尼)获纳入CSCO胆道恶性肿瘤诊疗指南(2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668794056","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668794056?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:50","pubTimestamp":1789728649,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114059583","title":"药捷安康-B旗下Yochanra（Tinengotinib）获CSCO指南收录，用于晚期胆道癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1114059583","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114059583?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:48","pubTimestamp":1789728510,"startTime":"0","endTime":"0","summary":"药捷安康-B传来重磅消息——其自主研发的候选药物Yochanra已被正式纳入《中国临床肿瘤学会指南》推荐，适用范围指向晚期胆道癌患者。据悉，CSCO指南是国内肿瘤诊疗领域极具权威性的参考文件，其收录与推荐，往往意味着药物的临床价值获得学界认可，也可能对其未来商业化前景产生积极影响。从研发层面看，Tinengotinib是一款多靶点激酶抑制剂，在胆道癌等难治性肿瘤适应症上展现出差异化的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153242951","title":"药捷安康-B（02617）自主创新药捷恩泰®进入2026年CSCO胆道恶性肿瘤诊疗指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1153242951","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153242951?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:46","pubTimestamp":1789728367,"startTime":"0","endTime":"0","summary":"2026年9月18日，药捷安康-B发布自愿性公告称，公司自主研发的多靶点小分子激酶抑制剂捷恩泰已被纳入《中国临床肿瘤学会胆道恶性肿瘤诊疗指南》，获评“II级推荐 2A类”，适用于晚期胆道恶性肿瘤治疗。捷恩泰于2026年8月6日获得国家药品监督管理局附条件批准上市，适应症为既往接受过系统性治疗和FGFR抑制剂治疗，并具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115218058","title":"药捷安康-B披露2026年8月股份变动月报表 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1115218058","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115218058?lang=zh_cn&edition=full","pubTime":"2026-09-02 18:44","pubTimestamp":1788345846,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年9月2日发布2026年8月股份变动月报表，报告期为2026年8月1日至8月31日。根据公告披露，公司普通股H股注册股本和非上市股份注册股本分别为312,687,673股和95,230,960股，总计407,918,633股，面值均为人民币1元，均与上期保持一致。整体来看，药捷安康-B 2026年8月股本结构维持稳定，未发生新的发行或回购活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790637","title":"药捷安康-B(02617.HK)发布中期业绩，净亏损9546.5万元，同比收窄22.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662790637?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:29","pubTimestamp":1787740187,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190344185","title":"药捷安康-B2026年上半年营收3,545.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190344185","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190344185?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:26","pubTimestamp":1787740009,"startTime":"0","endTime":"0","summary":"本季度信息\n药捷安康-B在截至2026年6月30日止六个月实现营收3,545.50万元，上年同期无营收。报告期内毛利同为3,545.50万元，毛利率为100%。期间公司进一步优化资源投入，研发成本为1.10亿元，同比增长11.7%；管理费用为2,306.00万元，同比下降16.1%。\n业务分项\n本期收入主要来自合作及授权协议的预付款。根据财报，暂无其他业务板块的详细财务数据披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B2026年上半年营收3,545.50万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111677564","title":"药捷安康-B：陈谭庆芬减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111677564","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111677564?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:16","pubTimestamp":1787649384,"startTime":"0","endTime":"0","summary":"陈谭庆芬于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。陈谭庆芬此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120152827","title":"药捷安康-B：Ghalibo (PTC) Limited减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120152827","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120152827?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:13","pubTimestamp":1787649224,"startTime":"0","endTime":"0","summary":"Ghalibo (PTC) Limited于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。Ghalibo (PTC) Limited此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190623156","title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190623156","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190623156?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:17","pubTimestamp":1787563066,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。Morningside Venture (I) Investments Limited此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136236588","title":"药捷安康-B（02617）公告将于2026年8月26日召开董事会审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1136236588","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136236588?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:01","pubTimestamp":1786698081,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司（02617）8月14日公告，公司董事会已决定于2026年8月26日（星期三）召开董事会会议。\n会议议程包括：  \n(i) 审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计综合中期业绩及其发布；  \n(ii) 研究宣派及派付2026年中期股息（如有）；  \n(iii) 处理其他相关事项。\n公告同时披露，截至公告日期，公司董事会成员包括：执行董事吴永谦博士、吴笛先生；非执行董事贾中新女士；独立非执行董事徐海音女士、冯维波先生及李书湃先生。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123933397","title":"药捷安康-B：CS Capital Co., Ltd.（国投招商投资管理有限公司）减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123933397","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123933397?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:15","pubTimestamp":1786353342,"startTime":"0","endTime":"0","summary":"CS Capital Co., Ltd.（国投招商投资管理有限公司）于2026年8月7日以每股均价13.74港元卖出药捷安康-B（02617）股份177.30万股，涉资约2436.10万港元。CS Capital Co., Ltd.（国投招商投资管理有限公司）此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143271311","title":"药捷安康-B：先进制造产业投资基金二期减持，好仓比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143271311","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143271311?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:11","pubTimestamp":1786353064,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) (先进制造产业投资基金二期 (有限合伙))于2026年8月7日以每股均价13.74港元卖出药捷安康-B 177.30万股H股，涉资约2436.10万港元。该基金此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660505","title":"药捷安康-B早盘涨超12% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660505","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657660505?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:45","pubTimestamp":1786067100,"startTime":"0","endTime":"0","summary":"模拟交易客户端药捷安康-B早盘高开逾28%，截至发稿，涨幅收窄，股价上涨12.06%，现报12.92港元，成交额2.26亿港元。药捷安康昨晚发布公告称，公司自主研发的1类新药捷恩泰获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。该疗法此前已获NMPA纳入优先审评及突破性治疗品种。据悉，该药物是药捷安康旗下首款获批上市的创新药。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-07/doc-inimmyem4200035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126093882","title":"异动解读｜药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1126093882","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126093882?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:30","pubTimestamp":1786066241,"startTime":"0","endTime":"0","summary":"8月7日，药捷安康-B盘中上涨21.51%，报14.04港元，成交额2036.61万港元。消息面上，公司8月6日公告，自主研发的1类新药捷恩泰获国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者治疗。此外，替恩戈替尼全球注册性III期临床试验已于7月完成入组，商业化前景进一步明朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667795","title":"港股异动 | 药捷安康-B(02617.HK)高开近15% 核心产品替恩戈替尼片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657667795?lang=zh_cn&edition=full","pubTime":"2026-08-07 09:24","pubTimestamp":1786065853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":0.162},{"period":"1month","weight":0.0786},{"period":"3month","weight":-0.0116},{"period":"6month","weight":-0.8385},{"period":"1year","weight":-0.9258},{"period":"ytd","weight":-0.9032}],"compareEarnings":[{"period":"1week","weight":0.005},{"period":"1month","weight":-0.0372},{"period":"3month","weight":0.0731},{"period":"6month","weight":-0.0116},{"period":"1year","weight":-0.0566},{"period":"ytd","weight":-0.0229}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}